Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IONS 
Ionis Pharmaceuticals Inc (IONS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: IONS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $59.19
1 Year Target Price $59.19
| 12 | Strong Buy |
| 5 | Buy |
| 8 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 44.01% | Avg. Invested days 66 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.79B USD | Price to earnings Ratio - | 1Y Target Price 59.19 |
Price to earnings Ratio - | 1Y Target Price 59.19 | ||
Volume (30-day avg) 26 | Beta 0.25 | 52 Weeks Range 23.95 - 49.08 | Updated Date 08/29/2025 |
52 Weeks Range 23.95 - 49.08 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When - | Estimate -0.24 | Actual 0.7 |
Profitability
Profit Margin -28.41% | Operating Margin (TTM) 30.93% |
Management Effectiveness
Return on Assets (TTM) -5.87% | Return on Equity (TTM) -59.91% |
Valuation
Trailing PE - | Forward PE 90.91 | Enterprise Value 5923265179 | Price to Sales(TTM) 7.2 |
Enterprise Value 5923265179 | Price to Sales(TTM) 7.2 | ||
Enterprise Value to Revenue 6.27 | Enterprise Value to EBITDA -22.08 | Shares Outstanding 159391008 | Shares Floating 157974241 |
Shares Outstanding 159391008 | Shares Floating 157974241 | ||
Percent Insiders 0.72 | Percent Institutions 108.54 |
Upturn AI SWOT
Ionis Pharmaceuticals Inc
Company Overview
History and Background
Ionis Pharmaceuticals, founded in 1989, pioneered antisense technology. It focuses on developing RNA-targeted therapeutics. Key milestones include the approval of Spinraza and collaborations with major pharmaceutical companies.
Core Business Areas
- Drug Discovery and Development: Focuses on discovering and developing new drugs using its antisense technology platform, targeting a wide range of diseases.
- Commercialization: Commercializes certain drugs independently or through partnerships. Spinraza is a prime example of partnered commercialization.
- Strategic Partnerships: Collaborates with other pharmaceutical companies to develop and commercialize its drugs. This strategy helps to broaden the reach of its pipeline.
Leadership and Structure
Brett P. Monia is the CEO. The company has a board of directors and a management team overseeing research, development, commercialization, and operations.
Top Products and Market Share
Key Offerings
- Spinraza (nusinersen): Spinraza is used for spinal muscular atrophy (SMA). Biogen commercializes it globally. Competitors include Zolgensma (gene therapy) by Novartis and Evrysdi (oral medication) by Roche.
- QUTIPA (eplontersen): QUTIPA (eplontersen) is used for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). Partnered with AstraZeneca. Competitors include Alnylam Pharmaceuticals' Onpattro and Amvuttra and Pfizer's Vyndaqel/Vyndamax.
- Wainua (eplontersen): Wainua (eplontersen) is used for transthyretin-mediated amyloid cardiomyopathy (ATTRcm). Partnered with AstraZeneca. Competitors include Alnylam Pharmaceuticals' Onpattro and Amvuttra and Pfizer's Vyndaqel/Vyndamax.
Market Dynamics
Industry Overview
The RNA-targeted therapeutics industry is growing, driven by advancements in technology and increasing understanding of RNA's role in disease. It is a competitive market.
Positioning
Ionis is a leader in antisense technology with a strong pipeline and established partnerships. Its competitive advantage lies in its proprietary technology and experience in RNA-targeted drug development.
Total Addressable Market (TAM)
The total addressable market for RNA therapeutics is substantial, estimated in the tens of billions of dollars. Ionis is well-positioned to capture a significant portion of this market through its diverse pipeline and partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary antisense technology platform
- Strong pipeline of drug candidates
- Established partnerships with major pharmaceutical companies
- Experience in RNA-targeted drug development
Weaknesses
- Reliance on partnerships for commercialization
- High research and development costs
- Regulatory hurdles for new drug approvals
- Competition from other RNA-targeted therapies
Opportunities
- Expansion of pipeline into new therapeutic areas
- Development of new RNA-targeted technologies
- Strategic acquisitions to broaden capabilities
- Increased adoption of RNA therapeutics
Threats
- Clinical trial failures
- Competition from generic drugs
- Changes in regulatory landscape
- Patent disputes
Competitors and Market Share
Key Competitors
- ALNY
- PFE
- NVS
- RHHBY
Competitive Landscape
Ionis competes with large pharmaceutical companies and specialized biotech firms. Its antisense technology is a differentiator, but it faces competition from other RNA-targeted therapies and traditional small molecule drugs.
Major Acquisitions
Akcea Therapeutics
- Year: 2020
- Acquisition Price (USD millions): 500
- Strategic Rationale: Consolidation of ownership and streamlining of operations.
Growth Trajectory and Initiatives
Historical Growth: Ionis's growth has been driven by successful drug approvals and partnerships. Revenue fluctuates depending on milestone payments and royalties.
Future Projections: Future growth depends on pipeline progress and commercial success of new drugs. Analysts' projections vary.
Recent Initiatives: Recent initiatives include advancing key pipeline programs and securing new partnerships. Wainua (eplontersen) approvals and commercialization are key recent initiatives.
Summary
Ionis Pharmaceuticals is a pioneering company in RNA-targeted therapeutics. Its strength lies in its proprietary antisense technology and partnerships, leading to FDA approval of products like Spinraza and Qutipa. Key areas to watch are pipeline progression, competition from other RNA therapies, and dependence on partnerships. Overall, Ionis holds a unique position, but must execute well to thrive in a challenging market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Ionis Pharmaceuticals' Investor Relations website
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share figures are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ionis Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 1991-05-17 | Founder, CEO & Director Dr. Brett P. Monia Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1069 | Website https://www.ionis.com |
Full time employees 1069 | Website https://www.ionis.com | ||
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.